Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.
about
Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.Updated recommendation on molecular-targeted therapy for metastatic renal cell cancer.Biomarkers defining probability of receiving second-line targeted therapy in metastatic renal cell carcinoma.Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.Non-Clear Cell Renal Cell Carcinoma: Current Management and Best Practice
P2860
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.
description
2017 nî lūn-bûn
@nan
2017 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Final overall survival analysi ...... everolimus in metastatic RCC.
@ast
Final overall survival analysi ...... everolimus in metastatic RCC.
@en
type
label
Final overall survival analysi ...... everolimus in metastatic RCC.
@ast
Final overall survival analysi ...... everolimus in metastatic RCC.
@en
prefLabel
Final overall survival analysi ...... everolimus in metastatic RCC.
@ast
Final overall survival analysi ...... everolimus in metastatic RCC.
@en
P2093
P2860
P356
P1433
P1476
Final overall survival analysi ...... y everolimus in metastatic RCC
@en
P2093
C H Barrios
L Geoffrois
N Berkowitz
P2860
P304
P356
10.1093/ANNONC/MDX075
P577
2017-06-01T00:00:00Z